PONENTE: A Multicenter, Open-label, Phase 3b Efficacy and Safety Study of Benralizumab 30 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Patients With Severe Eosinophilic Asthma on High Dose Inhaled Corticosteroid Plus Long-acting β2 Agonist and Chronic Oral Corticosteroid Therapy
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 14 Oct 2019
Price : $35 *
At a glance
- Drugs Benralizumab (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms PONENTE
- Sponsors AstraZeneca
- 10 Oct 2019 Planned End Date changed from 30 Oct 2020 to 3 Jul 2020.
- 10 Oct 2019 Planned primary completion date changed from 30 Oct 2020 to 3 Jul 2020.
- 10 Oct 2019 Status changed from recruiting to active, no longer recruiting.